Nothing is Forever Foundation Becomes Impact Investor in CureAge Therapeutics
The German Neurofibromatosis (NF) patient advocacy group will support CureAge’s mission to turn genetic therapies into cures for NF1 patients.
Nothing is Forever Foundation (NIF), a German non-profit organization committed to improving the quality of life of NF patients through novel treatments, has joined CureAge Therapeutics as an impact investor to accelerate the development of genetic therapies for NF1.
CureAge Therapeutics, founded by the Children’s Tumor Foundation (CTF) and Deep Science Ventures (DSV), is developing genetic medicines to halt, reverse, and potentially prevent plexiform neurofibromas in NF1 patients - a genetic condition affecting 3 million people worldwide that causes pain, disfigurement, and an increased risk of cancer.
“CureAge represents the type of innovation we seek, one that is carefully built in layers to push boundaries in the most de-risked and urgent way possible, and aimed at delivering long-term cures for NF patients,” said Josef Kammermeier, co-founder of NIF.
“Having Nothing is Forever join us not only provides crucial early-stage support but also reinforces our shared commitment to patients,” added Dr. Gonzalo Fernández-Miranda, CEO and co-founder of CureAge.
Advancing Toward In Vivo Proof-of-Concept
CureAge is raising funds to extend its Pre-Seed round and reach its next milestone: obtaining proof-of-concept in animal models. This data is critical for specialized investors and represents a pivotal step toward a potential curative therapy.
“The support of NF foundations and families is essential to maintain momentum and generate the data investors need,” said Dr. Fernández-Miranda.
CureAge is pioneering the use of lipid nanoparticles with a localized delivery route to either restore or eliminate tumor cells, preventing relapse and enabling long-lasting therapeutic benefit.
For more information about Nothing Is Forever, visit: nothing-is-forever.de.
To learn more about CureAge’s mission and scientific approach, visit cureagetx.com or connect on LinkedIn.